Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from MaxCyte ( (MXCT) ).
MaxCyte, Inc. announced the issuance of 97,857 shares of common stock as part of its block admission facility, following the exercise of share options and vesting of restricted stock units. This brings the total issued stock capital to 106,416,389 shares, which shareholders can use to calculate their interest in the company. This move reflects MaxCyte’s ongoing efforts to support its operations and strengthen its market position in the cell-engineering sector.
More about MaxCyte
MaxCyte, Inc. is a leading company in the cell-engineering industry, focusing on providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics. The company has developed the ExPERT™ platform, based on Flow Electroporation® technology, to support the expanding cell therapy market, offering a range of instruments, processing assemblies, and software protocols.
For detailed information about MXCT stock, go to TipRanks’ Stock Analysis page.